New Lab-Grown Islet Model Could Help Researchers Understand Type 1 Diabetes

Greenstone Biosciences has received a Breakthrough T1D Industry Discovery and Development Partnership (IDDP) grant to develop a novel research platform based on patient-derived insulin-producing cells. The project aims to create three-dimensional pancreatic islet organoids—lab-grown structures containing the β cells that produce insulin and are attacked by the immune system in Type 1 diabetes.

Type 1 diabetes affects over 9.5 million people globally, with projections showing this number could rise to 14.7 million by 2040. Despite the disease originating from an autoimmune attack on the pancreas, it shows significant variation from person to person, even among those with similar autoimmune markers.

A major challenge in Type 1 diabetes research has been the scarcity of human pancreatic tissue and the limitations of animal models, which don't fully capture how the human autoimmune system attacks the pancreas. Greenstone's approach addresses this by creating induced pluripotent stem cells (iPSCs) from a diverse group of Type 1 diabetes patients.

These patient-derived cells will be grown into 3D islet organoids in the laboratory, allowing researchers to study how insulin-producing cells respond to inflammation, metabolic stress, and experimental protective treatments in a system that more closely mirrors human biology.

With Breakthrough T1D support, Greenstone plans to develop what they describe as a scalable, multi-omics discovery engine—essentially a comprehensive platform that connects patient biology directly to therapeutic innovation. Such a resource could become a valuable tool for the broader Type 1 diabetes research community exploring new ways to protect or restore insulin-producing cells.

While this research represents an important step forward in understanding Type 1 diabetes at the cellular level, it is part of the broader, ongoing scientific effort to develop new treatments and preventive strategies.

Origin: sg.finance.yahoo.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.